Oakwood Laboratories is an Ohio specialist in long-acting injectable microspheres whose leuprolide depot formulations for prostate cancer went through the phase 3 trials it led.
Oakwood Laboratories, founded in 1997 in Oakwood Village, Ohio, develops sustained-release injectable microsphere formulations. Its leuprolide acetate depot products for advanced prostate cancer, developed to match the established monthly and three-monthly injections, were taken through phase 3 trials registered on ClinicalTrials.gov under Oakwood as lead sponsor, and the company also contract-manufactures depots for partners.
Leuprolide is the injectable that shuts off testosterone production, the foundation of hormone therapy for prostate cancer since the 1980s; it is also used for ovarian suppression in premenopausal breast cancer.
Shares Leuprolide (leuprorelin) and GnRH agonists, Pivotal (registrational) trial, Clinical trial, Prostate cancer.
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/